Education
About Us
Working with TipRanks
Follow Us
Barinthus Biotherapeutics (BRNS)
NASDAQ:BRNS
RESEARCH TOOLSreports
Total Valuation
Barinthus Biotherapeutics has a market cap or net worth of $40.23M. The enterprise value is -$52.10M.
Market Cap$40.23M
Enterprise Value-$52.10M
Share Statistics
Barinthus Biotherapeutics has 40,339,394 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,339,394
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Barinthus Biotherapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -46.25%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-46.25%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee142.56K
Profits Per Employee-582.70K
Employee Count105
Asset Turnover0.09
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Barinthus Biotherapeutics is -0.78. Barinthus Biotherapeutics’s PEG ratio is 0.04.
PE Ratio-0.78
PS Ratio0.00
PB Ratio0.37
Price to Fair Value0.37
Price to FCF-1.60
Price to Operating Cash Flow-1.65
PEG Ratio0.04
Income Statement
In the last 12 months, Barinthus Biotherapeutics had revenue of 14.97M and earned -61.07M in profits. Earnings per share was -1.55.
Revenue14.97M
Gross Profit14.97M
Operating Income-67.97M
Pretax Income-61.23M
Net Income-61.07M
EBITDA-55.37M
Earnings Per Share (EPS)-1.55
Cash Flow
In the last 12 months, operating cash flow was -24.63M and capital expenditures 1.67M, giving a free cash flow of -22.96M billion.
Operating Cash Flow-24.63M
Free Cash Flow-22.96M
Free Cash Flow per Share-0.57
Dividends & Yields
Barinthus Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.01
52-Week Price Change-57.87%
50-Day Moving Average0.91
200-Day Moving Average1.11
Relative Strength Index (RSI)57.73
Average Volume (3m)34.51K
Important Dates
Barinthus Biotherapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Barinthus Biotherapeutics as a current ratio of 8.03, with Debt / Equity ratio of 9.23%
Current Ratio8.03
Quick Ratio8.03
Debt to Market Cap0.25
Net Debt to EBITDA1.78
Interest Coverage Ratio-1.28K
Taxes
In the past 12 months, Barinthus Biotherapeutics has paid -153.00K in taxes.
Income Tax-153.00K
Effective Tax Rate<0.01
Enterprise Valuation
Barinthus Biotherapeutics EV to EBITDA ratio is 0.92, with an EV/FCF ratio of 1.71.
EV to Sales-3.41
EV to EBITDA0.92
EV to Free Cash Flow1.71
EV to Operating Cash Flow1.76
Balance Sheet
Barinthus Biotherapeutics has $110.66M in cash and marketable securities with $12.01M in debt, giving a net cash position of -$98.66M billion.
Cash & Marketable Securities$110.66M
Total Debt$12.01M
Net Cash-$98.66M
Net Cash Per Share-$2.45
Tangible Book Value Per Share$2.75
Margins
Gross margin is 100.00%, with operating margin of -454.07%, and net profit margin of -408.00%.
Gross Margin100.00%
Operating Margin-454.07%
Pretax Margin-409.03%
Net Profit Margin-408.00%
EBITDA Margin-369.92%
EBIT Margin-408.67%
Analyst Forecast
The average price target for Barinthus Biotherapeutics is $4.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$4.50
Price Target Upside354.55% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast1773.18%
EPS Growth Forecast19.16%